Roth Capital assumed coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research report released on Friday morning. The brokerage issued a buy rating and a $24.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Janney Montgomery Scott started coverage on shares of Recro Pharma in a research report on Monday, August 29th. They set a buy rating and a $21.00 target price on the stock. Brean Capital restated a buy rating and set a $28.00 target price on shares of Recro Pharma in a research report on Thursday, August 11th. HC Wainwright restated a buy rating on shares of Recro Pharma in a research report on Monday, July 18th. Finally, Zacks Investment Research upgraded shares of Recro Pharma from a sell rating to a hold rating in a research report on Thursday, July 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $18.95.

Shares of Recro Pharma (NASDAQ:REPH) opened at 9.16 on Friday. The firm’s 50-day moving average price is $9.30 and its 200 day moving average price is $7.87. The company’s market capitalization is $90.40 million. Recro Pharma has a 52-week low of $5.59 and a 52-week high of $15.75.

Recro Pharma (NASDAQ:REPH) last announced its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.05. The business had revenue of $17.30 million for the quarter, compared to analysts’ expectations of $18.70 million. Recro Pharma had a negative net margin of 8.70% and a negative return on equity of 52.80%. On average, equities analysts forecast that Recro Pharma will post ($3.13) earnings per share for the current year.

In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin acquired 390,000 shares of the company’s stock in a transaction dated Tuesday, August 16th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $2,925,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 39.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC increased its position in Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock worth $3,408,000 after buying an additional 191,796 shares in the last quarter. Vanguard Group Inc. increased its position in Recro Pharma by 0.4% in the second quarter. Vanguard Group Inc. now owns 107,252 shares of the specialty pharmaceutical company’s stock worth $852,000 after buying an additional 400 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock worth $397,000 after buying an additional 11,682 shares in the last quarter. Finally, BlackRock Fund Advisors increased its position in Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock worth $121,000 after buying an additional 4,163 shares in the last quarter. Hedge funds and other institutional investors own 36.38% of the company’s stock.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

5 Day Chart for NASDAQ:REPH

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.